• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Purchase of Xiidra

Quote




























anonymous said:
They are telling us that Novartis needs all of us. That we'll be kept and form our own xiidra force under Novartis.
Click to expand...
They are not telling us that.they only said that they bought the company along with 400 employees. That means any debts and obligations were transferred to Novartis. If you think they are keeping all those employees I have some great swamp land real estate for a cheap Price I can sell you. Great waterfront property.
 




















Good luck Shire/Takeda fools, Novarits likes to keep their sales teams lean. 400 reps is bigger then any division in Optha by double and there are plenty of products that makes way more then Xidra. It won't be cost effective to keep everyone especially with generic Restatis. You are all coming over so Takeda doesn't have to lay more of you off, my bet Novartis will.
 




anonymous said:
Good luck Shire/Takeda fools, Novarits likes to keep their sales teams lean. 400 reps is bigger then any division in Optha by double and there are plenty of products that makes way more then Xidra. It won't be cost effective to keep everyone especially with generic Restatis. You are all coming over so Takeda doesn't have to lay more of you off, my bet Novartis will.
Click to expand...
Not a very warm welcome to Novartis. Therefore, go to Hades loser!!
 




you don’t have one current product over 400 million plus with having the potential for 1 billion. They won’t need everyone but they will carry more reps than usudal because the market potential is too high and pipeline drugs are coming to fruition. You have to look at the whole picture.

All we be safe for 2019 for sure 2020 is talent selection so it’s everyones game. Hope your numbers don’t suck.
 




anonymous said:
Good luck Shire/Takeda fools, Novarits likes to keep their sales teams lean. 400 reps is bigger then any division in Optha by double and there are plenty of products that makes way more then Xidra. It won't be cost effective to keep everyone especially with generic Restatis. You are all coming over so Takeda doesn't have to lay more of you off, my bet Novartis will.
Click to expand...

This is 100% true regarding Takeda not having to lay off idiot xiidra reps now. Xiidra never fit shire and their rare disease/biologics push over the last 3 years. Neither does vyvanse. They tried to sell off the neuro side too but the vyvanse patent is up in less than 3 years and mydayis is a dog. The only reason they launched mydayis was in hopes it caught fire and was profitable.
 




















Top Bottom
Back
Quote